Edition:
United Kingdom

Oxford Immunotec Global PLC (OXFD.OQ)

OXFD.OQ on NASDAQ Stock Exchange Global Market

13.75USD
14 Dec 2017
Change (% chg)

$0.24 (+1.78%)
Prev Close
$13.51
Open
$13.50
Day's High
$13.82
Day's Low
$13.50
Volume
34,444
Avg. Vol
37,251
52-wk High
$19.50
52-wk Low
$12.20

Chart for

About

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company's product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and... (more)

Overall

Beta: -0.09
Market Cap(Mil.): $427.87
Shares Outstanding(Mil.): 25.51
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 168.71 16.44
EPS (TTM): -- -- --
ROI: -- 9.50 10.62
ROE: -- 14.87 14.20

BRIEF-Oxford Immunotec Global Plc says unit entered into a 2nd amendment to purchase agreement with Mabtech AB​

* Oxford Immunotec Global Plc - ‍on Nov 17, unit entered into a second amendment to purchase agreement with Mabtech AB​

21 Nov 2017

BRIEF-Oxford Immunotec Global Q3 loss per share $0.70

* Oxford Immunotec reports third quarter 2017 financial results

31 Oct 2017

BRIEF-Oxford Immunotec announces update in patent infringement litigation

* Oxford Immunotec announces update in patent infringement litigation

27 Sep 2017

BRIEF-Oxford Immunotec updates on amendment to supply agreement with StemCell Technologies ​

* Oxford Immunotec Global PLC - ‍on Sept 1 unit entered into second amendment to supply agreement with StemCell Technologies Canada f/k/a StemCell Technologies ​

06 Sep 2017

BRIEF-Oxford Immunotec appoints Stefan Linn as COO

* Oxford Immunotec appoints Stefan Linn as chief operating officer Source text for Eikon: Further company coverage:

30 Aug 2017

BRIEF-Oxford Immunotec Global Plc announces pricing of underwritten public offering of ordinary shares

* Oxford Immunotec Global Plc announces pricing of underwritten public offering of ordinary shares

15 Aug 2017

BRIEF-Oxford Immunotec Global announces agreement to sell 2.5 mln ordinary shares

* Oxford Immunotec Global Plc announces agreement to sell 2,500,000 ordinary shares

14 Aug 2017

BRIEF-Oxford Immunotec Q2 loss per share $0.74

* Oxford immunotec reports second quarter 2017 financial results

01 Aug 2017

BRIEF-Oxford Immunotec Global says unit entered into amendment to marketing authorization holder agreement with Riken Genesis

* Oxford Immunotec Global Plc - on july 24, unit of co entered into amendment to marketing authorization holder agreement with Riken Genesis Co., Ltd

28 Jul 2017

BRIEF-Oxford Immunotec appoints Richard Wenstrup, MD, as chief medical officer

* Oxford Immunotec appoints Richard Wenstrup, MD, as chief medical officer Source text for Eikon: Further company coverage:

24 Jul 2017

Competitors

Earnings vs. Estimates